from the Faculty of Pharmacy studied and combined three main immunotherapy strategies in : oncolytic adenoviruses, cancer vaccines, and immune checkpoint inhibitors.
Capasso has been a significant part in developing that combines the first two of the above-mentioned approaches and uses immunogenic viruses as active carriers of tumour-specific peptides. The peptides then direct the immune system to specifically target and kill cancer cells.
– It is nice for me to know that PeptiCRAd, as one of my very first projects, has reached the clinical trial stage via . It will be tested on humans next year. I am very lucky in seeing that my work can have such an impact on patients, and I feel very proud of it!
Immunotherapy relies on the patient’s own immune system and it is delivering impressive results at the moment, world-wide.
– Many drugs based on this principle are being approved on the market, Capasso describes.
__________________
Cristian Capasso will defend his doctoral dissertation entitled "" on 8 June 2018 at 12:15. The public examination will take place at Biocenter 2 (Viikinkaari 5), auditorium 1041.